Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan

Rhea-AI Filing Summary

Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Vlad Coric received an equity award of 4,545 Class A Ordinary Shares at no cost, reported as a grant under the company’s 2020 Independent Director Equity Incentive Plan. The award consists of restricted stock units scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the plan and award terms. Following this grant, Coric directly holds 15,343 Class A Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Coric Vlad

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	4,545	$0.00	--

Holdings After Transaction: Class A Ordinary Shares — 15,343 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 4,545 shares Grant price: $0.00 per share Post-grant holdings: 15,343 shares +2 more

5 metrics

RSU grant size 4,545 shares Restricted stock unit award to director Vlad Coric

Grant price $0.00 per share Price for the 4,545-share RSU award

Post-grant holdings 15,343 shares Class A Ordinary Shares held directly after transaction

Vesting schedule 100% at earlier of one year or next annual meeting Vesting terms for the RSU award under 2020 plan

Transaction date June 5, 2026 Date of RSU grant to Vlad Coric

Key Terms

restricted stock units, 2020 Independent Director Equity Incentive Plan, grant date, annual meeting of the Issuer's shareholders

4 terms

restricted stock units financial

"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Independent Director Equity Incentive Plan financial

"under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"

grant date financial

"vest 100% on the earlier of (i) the one-year anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

annual meeting of the Issuer's shareholders financial

"and (ii) the date of the annual meeting of the Issuer's shareholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coric Vlad

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	06/05/2026		A		4,545(1)	A	$0	15,343	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Vlad Coric	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Royalty Pharma (RPRX) director Vlad Coric report on this Form 4?

Vlad Coric reported receiving an equity grant of 4,545 Class A Ordinary Shares at no cost. The award is in the form of restricted stock units under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan.

How many Royalty Pharma shares does Vlad Coric hold after this RSU grant?

After the grant, Vlad Coric directly holds 15,343 Class A Ordinary Shares of Royalty Pharma. This figure includes the newly reported 4,545-share restricted stock unit award disclosed in the Form 4 filing.

What are the vesting terms of Vlad Coric’s 4,545 Royalty Pharma RSUs?

The 4,545 restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of Royalty Pharma’s next annual shareholder meeting, subject to the plan and award agreement.

Under which plan was Vlad Coric’s Royalty Pharma equity award granted?

The award was granted under Royalty Pharma’s 2020 Independent Director Equity Incentive Plan. This plan governs equity compensation for independent directors, including the restricted stock unit grant reported in this Form 4.

Did Vlad Coric buy or sell Royalty Pharma shares in the market in this filing?

The filing shows a grant of 4,545 Class A Ordinary Shares as a restricted stock unit award at a price of $0.00 per share. It does not report any open-market purchases or sales.